Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
Macarena I de la FuenteHoward ColmanMark RosenthalBrian A Van TineDanijela LevacicTobias WalbertHui K GanMaria VieitoMohammed M MilhemKathryn LipfordSanjeev ForsythSylvie M GuichardYelena MikhailovAlexander SedkovJulie BrevardPatrick F KellyHesham MohamedVarun MongaPublished in: Neuro-oncology (2022)
Olutasidenib 150 mg BID was well tolerated in patients with relapsed/refractory gliomas harboring an IDH1 R132X mutation and demonstrated preliminary evidence of clinical activity in this heavily pretreated population.